Narval develops Synthetic Antibody Mimetic Proteins (AMP) for localized therapeutic delivery via mucosal or skin tissues. These antibody-like proteins are designed to treat diseases in areas such as the eyes, lungs, and skin. The platform offers flexible, cost-effective biotherapeutics with reduced risk of systemic side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases affecting the eyes, lungs, and skin require localized treatment to minimize systemic side effects and improve efficacy. Traditional antibody drugs are often expensive and require specialized administration, limiting accessibility for many patients.
Solution
Narval is developing Synthetic Antibody Mimetic Proteins™ (AMP) for targeted treatment of diseases affecting mucosal or skin tissues. These AMPs are designed to be delivered locally to the eyes, lungs, or skin, providing an affordable and easy-to-use alternative to conventional antibody drugs. By focusing on localized delivery, Narval aims to reduce the risk of systemic side effects, thereby increasing treatment accessibility for a broader patient population. The company's approach seeks to create a new generation of antibody drugs that are both effective and convenient to administer.
Target Audience
The primary target audience includes patients suffering from diseases affecting the eyes, lungs, and skin who require localized treatment options, as well as healthcare providers seeking affordable and accessible antibody-based therapies.
Features
- Synthetic Antibody Mimetic Proteins™ (AMP) designed for localized delivery.
- Targeted treatment of diseases affecting the eyes, lungs, and skin.
- Mucosal or skin tissue delivery for direct application to the affected area.
- Affordable alternative to traditional antibody drugs.
- Reduced risk of systemic side effects compared to systemic treatments.
- Easy-to-use formulation for convenient administration.